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COUNTRIES
Leeuwenkamp O1, Perry R2, Morlock R3, Jones E2,Taylor T4
1Organon International, Molenstraat, Oss,The Netherlands, 2Adelphi
Group Products, Bollington, Cheshire, UK, 3Pﬁzer Inc, New York, NY,
USA, 4Pﬁzer, Ann Arbor, MI, USA
OBJECTIVES: To provide information on functional outcomes
for patients with schizophrenia manifesting negative symptoms
across ﬁve European countries. METHODS: Physicians in
France, Germany, Italy, Spain, and the UK who prescribed
antipsychotics for at least 15 patients with schizophrenia within
the preceding 3 months were invited to complete a questionnaire
concerning their patients’ clinical status and functional perfor-
mance. RESULTS: Data were obtained from 704 physicians
treating a total of 6569 patients from France (n = 1492),
Germany (n = 1439), Italy (n = 1002), Spain (n = 1310), and the
UK (n = 1326). Physicians rated patient symptoms on a 5-point
scale as either predominated by or with a high level of positive
symptoms (38%), predominated by or with a high level of neg-
ative symptoms (32%), or not dominated by either type of
symptom (22%). Physicians did not rate 8% of patients using
this scale. Patients with a predominance of negative symptoms
were rated as having signiﬁcantly greater functional impairment
than those with predominant positive symptoms as measured by
physician ratings on the Global Assessment of Functioning scale
(P < 0.01) and on 5-point global numerical ratings of overall
function, cognitive function, and patients’ overall ability to meet
their own needs (P < 0.01). In addition, 57% of patients in whom
negative symptoms predominated required a caregiver, compared
with 49%–50% of patients in other symptom categories. CON-
CLUSIONS: In this large, multinational, cross-sectional physi-
cian survey, patients with schizophrenia in whom negative
symptoms predominated had levels of functional impairment at
least as great as, if not greater than, those for patients in whom
positive symptoms predominated. These results suggest that
additional attention should be given to effectively treating the
persistent negative symptoms present in many patients with
schizophrenia.
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OBJECTIVES: To identify groups of patients with schizophrenia
with different compliance trajectories over three years and
explore causes, correlates and consequences. METHODS:
SOHO is an observational study of health outcomes in 10,000
patients with schizophrenia, from 10 countries, who initiated or
changed their antipsychotic medication. Prospective data was
available from seven measurement occasions over three years
and comprising patient and clinician reported antipsychotic com-
pliance, HRQL and side effects reported by patients, and clini-
cian CGI ratings. Latent class (group-based) mixture modeling,
following the methods developed by Nagin (1999) and Muthen
(2004), was applied to identify the prevalence, and graphically
characterize the proﬁle, of compliance trajectories over time
Model ﬁt was evaluated using Lo-Mendell-Rubin Likelihood
ratio tests, bootstrap p-values comparing n + 1 versus n latent
classes, and values of information criteria. Missing data were
included under a MAR assumption using maximum likelihood
estimation. RESULTS: Models with up to ﬁve classes were esti-
mated and four classes interpreted. The modal class identiﬁed
more than three quarters of the SOHO sample as largely com-
pliant throughout the study; three further latent classes identi-
ﬁed almost equal sized groups who increased or decreased their
compliance over time, or who never complied. Cross tabulation
of these latent compliance classes with classiﬁcations resulting
from modeling of longitudinal clinical symptom and HRQL data
revealed strong and statistically signiﬁcant associations thereby
illustrating co-evolution or linkage between parallel clinical,
compliance and health outcome processes. CONCLUSIONS:
Statistical summaries of longitudinal patterns offer important
insights into the dynamics of compliance, and can be used to
relate patterns of compliance with patterns of remission or
relapse on clinical symptom scales, or change in HRQL. Mixture
modelling of longitudinal data can be used to extend the propen-
sity score approach to longitudinal measurements of clinical
processes, which should characterize selection effects with higher
precision and greater clinical validity.
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OBJECTIVES: Utility scores are needed for computing Quality-
Adjusted Life Years (QALYs), commonly used as outcomes in
economic evaluations. Understanding patient preferences for
depression outcomes is important for economic evaluations of
new antidepressants, as well as for understanding patient behav-
iour and compliance to antidepressant regimens. METHODS:
A cross-sectional survey was carried out in order to evaluate
EuroQol scores in three proﬁles of Swedish outpatients suffering
from Major Depressive Disorder (MDD): patients experiencing
a new episode of MDD (“Non-treated” group), patients suc-
cessfully treated for eight weeks (“Responders” group) and
patients treated with an antidepressant for eight weeks and cur-
rently in relapse (“Relapsing” group). Patients were asked to ﬁll
in the EuroQol while the physicians were asked to ﬁll a stan-
dardised form. After applying the original social tariff proposed
by the EuroQol Group, patients’ sociodemographics were com-
pared to reveal potential confounders between stratiﬁcation
groups, and adjusted mean EuroQol scores were estimated and
compared using analysis of covariance. RESULTS: Nine psychi-
atrists and ﬁve general practitioners recruited a total of 205
patients (“Non-treated”: 61; “Responders”: 91; “Relapsing”:
53). No statistically signiﬁcant differences between groups were
found in terms of gender (Chi-square test: p = 0.156) or age
(ANOVA: p = 0.093). The overall EuroQoL score was 0.584 ±
0.304 (mean ± standard deviation), ranging between −0.239 
and 0.919. The “Responders” patients got signiﬁcantly higher
EuroQol scores (mean ± standard error) than the “Non-treated”
or the “Relapsing” patients (0.702 ± 0.033 vs. 0.482 ± 0.038 vs.
0.467 ± 0.043, respectively; p < 0.001 for both comparisons),
with differences clearly greater than the minimal clinically
important difference of 0.05. The “Non-treated” patients were
not statistically signiﬁcantly different from the “Relapsing”
patients (p = 0.961). CONCLUSIONS: Relapse in MDD appears
to be a very debilitating situation in terms of patient preferences,
since relapsing patients reported EuroQol scores slightly lower
than those reported by non-treated patients.
